Recruitment Status

Recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 8:40 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

22012

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Adenocarcinoma, Prostate Cancer, Neoplasms, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type
Interventions: TriAdeno vaccine, N-803; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency, Immune System Diseases, Autoimmune Lymphoproliferative, Lymphoproliferative Disorders
Interventions: Immunosuppression Only Conditioning -Closed with amendment L, Reduced Intensity Conditioning, Myeloablative Conditioning-Closed with amendment L, GVHD Prophylaxis, Allo BMT; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 4 Years to 75 Years
Enrollment: 354 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2036
U.S. locations: 2
States / cities: Bethesda, Maryland • Minneapolis, Minnesota

Conditions: Gulf War Illness
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 48 Years to 70 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Autoimmune Diseases
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years to 115 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Blood Donors, Research Subjects, Apheresis
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions: Personalized cardiac pacing; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 40 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 30
States / cities: Phoenix, Arizona • Palo Alto, California • San Francisco, California + 26 more

Conditions: Neurologic Disorders
Interventions: Laboratory tests, Radiological exams; Procedure
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 4 Years to 99 Years
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Major Depressive Disorder, Substance Use Disorder, Normal Physiology
Interventions: Placebo Nicotine Patch, Nicotine Patch; Other · Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 620 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mania, Bipolar Disorder
Interventions: Xanomeline/Trospium Chloride, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 22
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Bellflower, California + 19 more

Conditions: Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease
Interventions: Campath, Sirolimus, Base-edited hematopoietic stem and progenitor cells, Busulfan, Palifermin, Filgrastim, Plerixafor; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
Interventions: JNJ-79635322; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 9
States / cities: Duarte, California • Irvine, California • San Francisco, California + 5 more

Conditions: Dermatologic Conditions, Healthy Volunteers, Normal Volunteers, Carcinoma, Merkel Cell
Interventions: Not listed
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 1 Day to 100 Years
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2035
U.S. locations: 1
States / cities: Bethesda, Maryland

Recruiting clinical trials

Filter and sort this status page

Live official records

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

NIH Investigative Deep Phenotyping Study of Gulf War Veteran Health (Project NIH IN-DEPTH)

Deciphering the Genetic Architecture of Autoimmune Diseases

COLLECT BLOOD/RESEARCH USE

ELEVATE-HFpEF Clinical Study

Evaluation and Treatment of Neurosurgical Disorders

Defining Neurobiological Links Between Substance Use and Mental Illness

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Studies of Dermatologic Diseases Biospecimen Acquisition Protocol